REGULATORY

• Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
  October 30, 2025

• Japan PM Warns of Overreliance on China for Pharmaceutical Ingredients
  October 29, 2025

• Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
  October 29, 2025

• Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
  October 28, 2025

• Takaichi Vows Cross-Party Talks on Social Security Reform
  October 27, 2025

• Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
  October 27, 2025

• Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
  October 27, 2025

• Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
  October 27, 2025

• Makoto Oniki Tapped as Head of LDP’s Health Division
  October 27, 2025

• MHLW Outlines 4 Key Themes for 2026 Reform, Eyes OTC-Like Meds, CEA for Efficiency
  October 24, 2025

• MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
  October 23, 2025

• New Health Minister Pledges to Strengthen Japan’s Drug Discovery Capabilities
  October 23, 2025

• LDP’s Nagasaka Appointed Senior Vice Health Minister; Niki to Stay On
  October 23, 2025

• Public-Private WG to Compile Industry Proposals on Drug Pricing Reforms at Next Session
  October 23, 2025

• MHLW Orders Label Revisions for Amitiza, Shingrix, and More
  October 23, 2025

• Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
  October 22, 2025

• LDP’s Takaichi Elected as Japan’s First Female Prime Minister
  October 22, 2025

• LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
  October 21, 2025

• No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
  October 20, 2025

• Payers, Providers Clash over Fate of Fee Premiums for Generic Use
  October 20, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• …
• Next ›
• 最終 »